CapsoVision Q2 FY26 operating loss widens to $7.58 million; revenue rises 10% to $3.6 million
Reuters2026/08/13 20:08- CapsoVision posted Q2 revenue of $3.6 million, up 10% year over year.
- Operating loss widened to $7.58 million; net loss deepened to $7.48 million, or $(0.15) a share.
- Gross margin fell 4 percentage points to 51% on selling-price pressure and higher customs and tariff costs.
- Operating expenses climbed to $9.5 million, driven by colon pivotal-study spending, other trials, Canon engineering work, public-company costs, stock-based compensation.
- AI Highlights launched commercially in the EU; FDA clearance expected by end-Q3 2026, with U.S. launch planned soon after.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs remains bullish on the South Korean stock market: Driven by the AI memory boom, with a potential upside of up to 80%.
Goldman Sachs strategist Timothy Moe maintains his bullish target on the South Korean stock market, believing that investors are underestimating how long the benefits of artificial intelligence (AI) will last for the country's memory chip manufacturers.
Oranjebtc cancels 25 million treasury shares without capital reduction
The Last Time Treasury Yields Hit 6%, Bitcoin Didn't Exist — What Happens If They Get There Again?
Crypto prices
More
